H2N2V1, Main, Exploration, bibRecord, 001D39

Recent developments in the design of antiviral agents

Identifieur interne : 001D39 ( Main/Exploration ); précédent : 001D38; suivant : 001D40

Recent developments in the design of antiviral agents

Auteurs : John Saunders [Royaume-Uni] ; Janet M. Cameron [Royaume-Uni]

Source :

Medicinal Research Reviews [ 0198-6325 ] ; 1995-11.

RBID : ISTEX:68E2843177AEE68ED887097BB7EAD7A1E348BE9E

English descriptors

Teeft :
- 3tcr viruses, Active site, Acyclovir, Acyclovir triphosphate, Agents chemother, Analogue, Antigenic drift, Antimicrob, Antiviral, Antiviral agents, Antiviral drugs, Antiviral therapy, Assay, Better understanding, Biochemical pharmacology, Bone marrow toxicity, Cameron, Cammack, Carbocyclic bvdu, Catalytic apparatus, Cell numbers, Cell surface, Chain terminator, Chain terminators, Chemother, Chronic carriers, Chronic disease, Chronic hepatitis, Chronic phase, Clinical trial, Clinical trials, Codon, Competitive inhibitor, Competitive inhibitors, Compound, Cytidine deaminase, Cytokine production, Cytomegalovirus, Cytopathic effect, Disease progression, Dos, Drug resistance, Drug therapy, Early development, Emergence, Enzymatic reaction, Enzyme, European lamivudine, Foscarnet, Further analysis, Further trials, Ganciclovir, Gene products, General introduction, Genetic information, Genome, Hepatitis, Hepatitis virus, Hepatitis viruses, Herpes, Herpes virus replication, Herpes viruses, Host cell, Host cell membrane, Host genome, Human herpes viruses, Human herpesvirus, Immune, Immune response, Infection, Influenza, Influenza neuraminidase, Influenza virus, Influenza virus infection, Inhibitor, International congress, Intracellular, Intranasal route, Kinase, Lamivudine, Lung homogenates, Medical virology, Medicinal chemistry, Methyl acrylate, Molecular biology, Monkey model, Mouse model, Mutation, Neuraminidase, Nucleic acid, Nucleoside, Nucleoside analogues, Oral bioavailability, Other agents, Other nucleoside analogues, Other retroviruses, Oxathiolane ring, Parainfluenza virus, Peripheral neuropathy, Pharmacokinetic properties, Polymerase, Polymerase activity, Polymerase domain, Polymerase gamma, Polymerase proteins, Polymerase triphosphate, Poor pharmacokinetics, Potent inhibitor, Potent inhibitors, Primer, Primer protein, Progeny virus, Protease, Protease inhibitor, Rash formation, Recent developments, Recurrent disease, Replication, Resistant strains, Resistant virus, Respiratory tract, Ring opening, Same time, Saunders, Sexual contact, Sialic, Sialic acid, Sialidase, Sialidase activity, Silylated cytosine, Storer, Surface antigen, Table viii, Thymidine, Toxicity, Transcriptase, Triphosphate, Vaccine, Varicella zoster virus, Vesicular lesions, Viral, Viral diseases, Viral genome, Viral load, Viral particles, Viral polymerase, Viral proteins, Viral replication, Virally, Virion, Virology, Virus, Virus infection, Virus infections, Virus replication, Virus research, Water molecule, Wild type virus.

Url:

https://api.istex.fr/ark:/67375/WNG-HMTB6WC7-Z/fulltext.pdf

DOI: 10.1002/med.2610150604

Affiliations:

Royaume-Uni

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 001773
to stream Istex, to step Curation: 001773
to stream Istex, to step Checkpoint: 000B14
to stream Main, to step Merge: 001E13
to stream Main, to step Curation: 001D39

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recent developments in the design of antiviral agents</title>
<author><name sortKey="Saunders, John" sort="Saunders, John" uniqKey="Saunders J" first="John" last="Saunders">John Saunders</name>
</author>
<author><name sortKey="Cameron, Janet M" sort="Cameron, Janet M" uniqKey="Cameron J" first="Janet M." last="Cameron">Janet M. Cameron</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:68E2843177AEE68ED887097BB7EAD7A1E348BE9E</idno>
<date when="1995" year="1995">1995</date>
<idno type="doi">10.1002/med.2610150604</idno>
<idno type="url">https://api.istex.fr/ark:/67375/WNG-HMTB6WC7-Z/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001773</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001773</idno>
<idno type="wicri:Area/Istex/Curation">001773</idno>
<idno type="wicri:Area/Istex/Checkpoint">000B14</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000B14</idno>
<idno type="wicri:doubleKey">0198-6325:1995:Saunders J:recent:developments:in</idno>
<idno type="wicri:Area/Main/Merge">001E13</idno>
<idno type="wicri:Area/Main/Curation">001D39</idno>
<idno type="wicri:Area/Main/Exploration">001D39</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Recent developments in the design of antiviral agents</title>
<author><name sortKey="Saunders, John" sort="Saunders, John" uniqKey="Saunders J" first="John" last="Saunders">John Saunders</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Departments of Medicinal Chemistry II, Gunnels Wood Road, Stevenage</wicri:regionArea>
<wicri:noRegion>Stevenage</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cameron, Janet M" sort="Cameron, Janet M" uniqKey="Cameron J" first="Janet M." last="Cameron">Janet M. Cameron</name>
<affiliation wicri:level="1"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Virology, Glaxo Research and Development Limited, Gunnels Wood Road, Stevenage</wicri:regionArea>
<wicri:noRegion>Stevenage</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Medicinal Research Reviews</title>
<title level="j" type="alt">MEDICINAL RESEARCH REVIEWS</title>
<idno type="ISSN">0198-6325</idno>
<idno type="eISSN">1098-1128</idno>
<imprint><biblScope unit="vol">15</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="497">497</biblScope>
<biblScope unit="page" to="531">531</biblScope>
<biblScope unit="page-count">35</biblScope>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="1995-11">1995-11</date>
</imprint>
<idno type="ISSN">0198-6325</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0198-6325</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>3tcr viruses</term>
<term>Active site</term>
<term>Acyclovir</term>
<term>Acyclovir triphosphate</term>
<term>Agents chemother</term>
<term>Analogue</term>
<term>Antigenic drift</term>
<term>Antimicrob</term>
<term>Antiviral</term>
<term>Antiviral agents</term>
<term>Antiviral drugs</term>
<term>Antiviral therapy</term>
<term>Assay</term>
<term>Better understanding</term>
<term>Biochemical pharmacology</term>
<term>Bone marrow toxicity</term>
<term>Cameron</term>
<term>Cammack</term>
<term>Carbocyclic bvdu</term>
<term>Catalytic apparatus</term>
<term>Cell numbers</term>
<term>Cell surface</term>
<term>Chain terminator</term>
<term>Chain terminators</term>
<term>Chemother</term>
<term>Chronic carriers</term>
<term>Chronic disease</term>
<term>Chronic hepatitis</term>
<term>Chronic phase</term>
<term>Clinical trial</term>
<term>Clinical trials</term>
<term>Codon</term>
<term>Competitive inhibitor</term>
<term>Competitive inhibitors</term>
<term>Compound</term>
<term>Cytidine deaminase</term>
<term>Cytokine production</term>
<term>Cytomegalovirus</term>
<term>Cytopathic effect</term>
<term>Disease progression</term>
<term>Dos</term>
<term>Drug resistance</term>
<term>Drug therapy</term>
<term>Early development</term>
<term>Emergence</term>
<term>Enzymatic reaction</term>
<term>Enzyme</term>
<term>European lamivudine</term>
<term>Foscarnet</term>
<term>Further analysis</term>
<term>Further trials</term>
<term>Ganciclovir</term>
<term>Gene products</term>
<term>General introduction</term>
<term>Genetic information</term>
<term>Genome</term>
<term>Hepatitis</term>
<term>Hepatitis virus</term>
<term>Hepatitis viruses</term>
<term>Herpes</term>
<term>Herpes virus replication</term>
<term>Herpes viruses</term>
<term>Host cell</term>
<term>Host cell membrane</term>
<term>Host genome</term>
<term>Human herpes viruses</term>
<term>Human herpesvirus</term>
<term>Immune</term>
<term>Immune response</term>
<term>Infection</term>
<term>Influenza</term>
<term>Influenza neuraminidase</term>
<term>Influenza virus</term>
<term>Influenza virus infection</term>
<term>Inhibitor</term>
<term>International congress</term>
<term>Intracellular</term>
<term>Intranasal route</term>
<term>Kinase</term>
<term>Lamivudine</term>
<term>Lung homogenates</term>
<term>Medical virology</term>
<term>Medicinal chemistry</term>
<term>Methyl acrylate</term>
<term>Molecular biology</term>
<term>Monkey model</term>
<term>Mouse model</term>
<term>Mutation</term>
<term>Neuraminidase</term>
<term>Nucleic acid</term>
<term>Nucleoside</term>
<term>Nucleoside analogues</term>
<term>Oral bioavailability</term>
<term>Other agents</term>
<term>Other nucleoside analogues</term>
<term>Other retroviruses</term>
<term>Oxathiolane ring</term>
<term>Parainfluenza virus</term>
<term>Peripheral neuropathy</term>
<term>Pharmacokinetic properties</term>
<term>Polymerase</term>
<term>Polymerase activity</term>
<term>Polymerase domain</term>
<term>Polymerase gamma</term>
<term>Polymerase proteins</term>
<term>Polymerase triphosphate</term>
<term>Poor pharmacokinetics</term>
<term>Potent inhibitor</term>
<term>Potent inhibitors</term>
<term>Primer</term>
<term>Primer protein</term>
<term>Progeny virus</term>
<term>Protease</term>
<term>Protease inhibitor</term>
<term>Rash formation</term>
<term>Recent developments</term>
<term>Recurrent disease</term>
<term>Replication</term>
<term>Resistant strains</term>
<term>Resistant virus</term>
<term>Respiratory tract</term>
<term>Ring opening</term>
<term>Same time</term>
<term>Saunders</term>
<term>Sexual contact</term>
<term>Sialic</term>
<term>Sialic acid</term>
<term>Sialidase</term>
<term>Sialidase activity</term>
<term>Silylated cytosine</term>
<term>Storer</term>
<term>Surface antigen</term>
<term>Table viii</term>
<term>Thymidine</term>
<term>Toxicity</term>
<term>Transcriptase</term>
<term>Triphosphate</term>
<term>Vaccine</term>
<term>Varicella zoster virus</term>
<term>Vesicular lesions</term>
<term>Viral</term>
<term>Viral diseases</term>
<term>Viral genome</term>
<term>Viral load</term>
<term>Viral particles</term>
<term>Viral polymerase</term>
<term>Viral proteins</term>
<term>Viral replication</term>
<term>Virally</term>
<term>Virion</term>
<term>Virology</term>
<term>Virus</term>
<term>Virus infection</term>
<term>Virus infections</term>
<term>Virus replication</term>
<term>Virus research</term>
<term>Water molecule</term>
<term>Wild type virus</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>Royaume-Uni</li>
</country>
</list>
<tree><country name="Royaume-Uni"><noRegion><name sortKey="Saunders, John" sort="Saunders, John" uniqKey="Saunders J" first="John" last="Saunders">John Saunders</name>
</noRegion>
<name sortKey="Cameron, Janet M" sort="Cameron, Janet M" uniqKey="Cameron J" first="Janet M." last="Cameron">Janet M. Cameron</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D39 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D39 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:68E2843177AEE68ED887097BB7EAD7A1E348BE9E
   |texte=   Recent developments in the design of antiviral agents
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021

	Serveur d'exploration H2N2
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration H2N2

Recent developments in the design of antiviral agents

Recent developments in the design of antiviral agents

Source :

English descriptors

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri